New drug trial targets rare, dangerous blood clots
NCT ID NCT07459114
Summary
This early-stage trial is testing a new drug called TGD001 for people experiencing acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) and related blood clotting disorders. The study will first find a safe dose and then test how well it works when added to standard care. Researchers aim to see if TGD001 can help reduce dangerous blood clots and improve recovery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.